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Mutations affecting the secretory COPII coat component
SEC23B cause congenital dyserythropoietic anemia
type II
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Barry H Paw7, Karl-Peter Hopfner8, Karlheinz Holzmann9, Roberta Russo3, Maria Rosaria Esposito3,
Daniela Spano3, Luigia De Falco3, Katja Heinrich1, Brigitte Joggerst4, Markus T Rojewski1,2, Silverio Perrotta10,
Jonas Denecke11, Ulrich Pannicke1, Jean Delaunay12, Rainer Pepperkok4 & Hermann Heimpel13
Congenital dyserythropoietic anemias (CDAs) are
phenotypically and genotypically heterogeneous diseases1–4.
CDA type II (CDAII) is the most frequent CDA. It is
characterized by ineffective erythropoiesis and by the presence
of bi- and multinucleated erythroblasts in bone marrow, with
nuclei of equal size and DNA content, suggesting a cytokinesis
disturbance5. Other features of the peripheral red blood cells
are protein and lipid dysglycosylation and endoplasmic
reticulum double-membrane remnants4,6. Development of
other hematopoietic lineages is normal. Individuals with CDAII
show progressive splenomegaly, gallstones and iron overload
potentially with liver cirrhosis or cardiac failure. Here we show
that the gene encoding the secretory COPII component
SEC23B is mutated in CDAII. Short hairpin RNA (shRNA)-
mediated suppression of SEC23B expression recapitulates the
cytokinesis defect. Knockdown of zebrafish sec23b also leads
to aberrant erythrocyte development. Our results provide
in vivo evidence for SEC23B selectivity in erythroid
differentiation and show that SEC23A and SEC23B, although
highly related paralogous secretory COPII components,
are nonredundant in erythrocyte maturation.
We studied 33 individuals with congenital dyserythropoietic anemia
type II (CDAII; MIM224100) from 28 unrelated families (Supple-
mentary Table 1) of various ancestral backgrounds. CDAII was
diagnosed on the basis of previously published criteria7, including
clinical aspects, bone marrow morphology and anomalous erythro-
cyte membrane proteins (Supplementary Table 1). In five families,
the parents are consanguinous (F2, F6, F11, F16, F18). Assuming a
recessive inheritance model, we conducted a screen for homozygous
chromosomal regions using genome-wide SNP analysis for individuals
F6P1 and F11P1. This analysis revealed a single common homozygous
region on chromosome 20p11.23–20p12.1 (Supplementary Table 2),
flanked by KIF16B on the telomeric side and SLC24A3 on the
centromeric side and encompassing 23 ORFs. The CDAII locus was
originally mapped to 20q11 (ref. 8). In a refined contig build (build
36.3), the markers with the highest CDAII lod scores overlap the
minimal homozygosity region on the short arm of chromosome 20
(ref. 9). The amalgamation of these results with the proposition of
impaired cis, medial and trans N-glycan Golgi processing of erythro-
blast glycoproteins in CDAII10 made secretory pathway components
potential candidates. We therefore sequenced the SEC23B gene, which
is located in the critical region and encodes a COPII component, in all
33 individuals. We detected 12 different missense mutations, five
nonsense mutations, one single-nucleotide as well as one large
deletion and one splice-site mutation (Fig. 1a and Supplementary
Table 3). Seventeen individuals are compound heterozygotes, whereas
16 individuals, including the eight in the five consanguinous families,
are homozygotes. Every case bears at least one missense mutation,
suggesting that the presence of two severe mutations may be lethal.
There are two hot spots of mutation, with 325G4A accounting for
30% (20 of 66 alleles) and 40C4T for 15% (10 of 66 alleles) of
the mutations. Haplotype analyses failed to demonstrate the existence
of a founder effect (data not shown). When data on parents were
available, we found that parents were heterozygous for the muta-
tions, excluding the occurrence of de novo mutations in these
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individuals and supporting autosomal recessive inheritance (Supple-
mentary Table 3). The mutations affect most domains of SEC23B;
only the C-terminal gelsolin-like domain is spared (Fig. 1a). All
missense mutations affect highly conserved residues (Supplementary
Table 4). From our analyses, we conclude that most individuals with
CDAII bear SEC23B mutations.
In healthy subjects, the mutation 790C4T was heterozygously
detected once in 237 individuals, and the substitution 276G4A was
present heterozygously 24 times in 354 subjects (6.7%). Changes
present more than once in the cohort were not detected in at least
237 healthy individuals; sporadic mutations were never seen on 200
chromosomes of healthy subjects.
SEC23B missense mutations of F4P1 and F6P1 showed no gross
influence on SEC23B RNA stability (Fig. 1b). In contrast, the F4P1
RNA with the exon 3+4 deletion was barely detectable, possibly owing
to a frameshift and premature stop codon resulting in nonsense-
mediated decay (Fig. 1b). We observed normal SEC23B RNA expres-
sion in peripheral blood of F20P1 and F26P1 by RT-PCR (data not
shown). No alternative SEC23B splice products were detectable in
mononuclear cells of bone marrow and blood, K562 erythroleukemic
cells and normal dermal fibroblasts (Fig. 1b).
By protein blotting, we quantified with different polyclonal
antibodies SEC23B and total SEC23 (A and B) proteins in control
and F4P1 fibroblasts (Fig. 1b). Evaluation of three independent
experiments showed that the cell line of the affected individual had
38% ± 7% of SEC23B, and total SEC23 was
67% ± 9% when normalized to the 100% in
the control.
The secretory pathway in eukaryotic cells is
critical for membrane homeostasis, localiza-
tion of proteins within cells and secretion of extracellular factors.
During a budding reaction, cytoplasmic coat proteins (COPs) are
assembled on a membrane surface, capture cargo molecules and
polymerize into a cage sculpting different-sized cargo vesicles. In
yeast, COPII-coated vesicles form by the sequential binding of Sar1-
GTP, the inner complex proteins Sec23–Sec24 and the outer complex
components Sec13–Sec31 on the endoplasmic reticulum (ER)11,12.
Sec23–Sec24 is implicated in selective cargo sorting destined for the
cis-Golgi apparatus but has additional roles in completion of the coat
assembly, tethering of vesicles to their targets and regulating traffic13.
For Sec23, additional roles in autophagy and in receptor internaliza-
tion have been claimed14,15.
To analyze potential mechanistic consequences of the identified mis-
sense mutations, we generated a model of human SEC23B (Fig. 1c) on
the basis of the highly related (Supplementary Table 4) human SEC23A
crystal structure16. Mutations severely truncating SEC23B are unlikely
to give a soluble, stable and folded peptide. R18H, V426I, Y462C, A524V
and R530W are located in or near the core structures of SEC23B. These
mutations might destabilize the protein or perturb the fold. R14W, E109K
and R497C are located in the zinc-finger domain or at its interface with
other domains. These mutations likely disrupt the function or orientation
of the zinc-finger domain or may affect protein-protein interactions.
D239G is situated near the SEC24 binding site and may interfere with
proper SEC24 interaction. R313H and I318T are near the SAR1 binding
site in a region where SEC31 also binds. These mutations could perturb
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Figure 1 SEC23B mutation analysis. (a) SEC23B
mutations are projected on the schematic domain
structure of SEC23B. Mutations are indicated in
blue when detected in more than one kindred.
(b) Upper panel shows SEC23B RT-PCR of
normal and two affected individuals (F4P1, F6P1)
fibroblasts, K562 cells and normal mononuclear
cells (MNC) of bone marrow (BM) and peripheral
blood (pB). (For BM2, only 20% of RNA was
used as compared to the other analyses. For MNC
BM1, MNC BM2 and MNC pB, the gel loading
was doubled.) Lower panels show quantity of
SEC23B and total SEC23 protein as analyzed by
protein blot in a control (C) and an affected
individual (AI) cell line (F4P1). Quantification of
three independent experiments shows that the
patient cell line has 38% ± 7% of SEC23B
compared to control. Total SEC23 is 67% ± 9%
of control. Tubulin detection was used as loading
control. (c) Model of human SEC23B shown as
ribbon plot with highlighted secondary structure.
The model was generated on the basis of the
crystal structure of human SEC23A. The side
chains of mutated residues in SEC23B are shown
as green spheres. Binding sites for known
interaction partners are indicated16,23–25.
(d) Dilution analysis of SEC23B wild-type
and mutants overexpressed after transient
transfections in HEK293T cells. The EGFP
signal is for the transfection and loading control.
(e) Coimmunoprecipitation of SEC23B wild-type
and mutants. The presence (+) or absence () of
the antibody to V5 is indicated.
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interaction with SAR1 and/or SEC31. Finally, Q386R is located near the
SEC31 binding groove and likely interferes with SEC31 binding.
For protein studies, we selected one zinc-finger domain (E109K)
mutant and one mutant situated at the interface of the zinc-finger
domain and SEC23B core fold (R14W) (both together account for
about 50% of the mutations) as well as the mutant D239G, which is
situated near the SEC24 binding site. Overexpression of C-terminally
tagged SEC23B mutants by transient transfection in HEK293T cells
revealed the instability of the zinc-finger–associated mutants, with less
than 5% of protein detectable compared to wild-type SEC23B
(Fig. 1d), supporting the results of primary fibroblast analyses. The
D239G mutation did not impair SEC23B stability (Fig. 1d).
To unravel potential functional consequences of the three mutant
proteins, we carried out coimmunoprecipitation experiments with
V5-C-terminally labeled SEC24D, a SEC24 isoform previously impli-
cated in SEC23A binding17. All three mutants (E109K, R14W and
D239G) were coimmunoprecipitated by SEC24D with similar
SEC23B/SEC24D ratios as in crude cell extracts (Fig. 1e), implying
that the overall structure and the SEC23B–SEC24D interface of
the mutants is not disordered. Similar results were obtained with
SEC24C (data not shown).
Why does impairment of SEC23B lead to such a specific erythro-
poietic phenotype, considering its central role in secretion? In
humans, two SEC23 isoforms, SEC23A and SEC23B, have been
noted. We suspected that the CDAII phenotype may be caused by
tissue-specific expression of SEC23A versus SEC23B. We observed no
gross RNA expression difference between the paralogs in primary
dermal fibroblasts (data not shown). When in vitro erythroid differ-
entiation of CD34+ blood cells was conducted for 7–14 d, SEC23B
RNA expression increased 5–7 fold over SEC23A RNA expression
(Fig. 2a), whereas in the seeded CD34+ cells, the relative expression
levels were equal. Protein blot analysis revealed an increased amount
of SEC23B protein in CD34+ blood cells 14 d after differentiation
initiation as compared to 7 d (Fig. 2a). We did not analyze SEC23A at
the protein level because we lacked a suitable specific antibody.
To imitate SEC23B protein reduction in individuals with CDAII
and to elucidate the functional role of SEC23B downregulation, we
generated stable pools of the erythroleukemic cell line K562 after
transfection with a translation-interfering SEC23B-silencing shRNA-
mir vector and control vectors. We observed no difference of SEC23B
RNA expression in silenced and nonsilenced K562 pools (Fig. 2b).
SEC23B protein expression in SEC23B-silenced K562 pools was 44.8%
compared to K562, and 64.0% compared to the nonsilenced shRNA-
mir pools (Fig. 2b). After SEC23B silencing of K562, FACS cell cycle
analysis showed a threefold increase of the percentage of cells in the
G2+M phase (that is, cells containing twice the amount of DNA) over
controls (P ¼ 0.02) (Fig. 2c). This observation prompted the question
of whether the increased percentage of cells with double DNA content
may be in part due to binucleated cells. Microscopy of stable pools
stained with 4,6-diamidino-2-phenylindole (DAPI) showed the
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Figure 2 SEC23B expression and function in erythroid cells. (a) Left panel shows gene expression analyses of SEC23A and SEC23B during in vitro erythroid
differentiation of peripheral blood CD34+ cells from healthy controls as assessed by qRT-PCR. At 7 d after erythropietin (EPO) treatment, SEC23B showed
an increased expression (0.05 ± 0.004, mean ± s.d) compared with SEC23A gene expression (0.01 ± 0.002; P ¼ 0.0001, Student’s t-test). This difference
is more visible 14 d after differentiation (SEC23B 0.07 ± 0.006 versus SEC23A 0.01 ± 0.002, P ¼ 0.0001, Student’s t-test). Right panel shows protein
blot analysis of SEC23B expression during in vitro erythroid differentiation of peripheral blood CD34+ cells from healthy controls. (b) Left panel shows
SEC23B RNA expression analysis of K562 stable pools. No significant variation in SEC23B-silenced cells was observed when compared to the controls
(mean ± s.d.). Right panels show SEC23B protein expression in K562 stable pools. Decreased protein expression in K562 stable pools silenced for SEC23B
is 55.2% compared to K562 wild-type, and 36.0% compared to K562 treated with nonsilencing shRNAmir (*P ¼ 0.03; Student’s t-test). (c) Cell cycle
analyses of K562 stable pools (one of three experiments). The black line shows all detected cells, the high red peak represents the cells in G0+G1 phases,
the hatched area are the cells in S phase and the low red peak are the cells in G2+M phases. The diagram summarizes triplicate results for each cell cycle
phase (mean ± s.e.m.). A significant increase of the cell percentage silenced for SEC23B in the G2+M phase (10.3% ± 1.4) when compared to control
stable pools (pSM2, 3.2% ± 1.7, **P ¼ 0.02; nonsilencing shRNAmir, 2.9% ± 1.7, *P ¼ 0.02; Student’s t-test) was observed. (d) Microscopic analysis
of K562 stable pools with the presence of binucleated cells in SEC23B-silenced cells after DAPI (indices 3, 6, 7) or hematoxylin-eosin (index 8) staining.
Comparison of the nuclei major and minor axes between control pools and SEC23B-silenced K562 pool. Detection of an increased major axis in silenced
cells (97.8 ± 2.3 pixels) compared to PSM2 cells (83.1 ± 2.8, P ¼ 0.0002) and to nonsilenced cells (82.8 ± 2.4, P ¼ 0.0001) (Student’s t-test) and
an increased minor axis in silenced cells (78.7 ± 3.5 pixels) compared to PSM2 cells (53.1 ± 3.4, P ¼ 0.00001) and to nonsilenced cells (59.6 ± 2.4,
P ¼ 0.0001) (Student’s t-test). Data are shown as mean ± s.e.m.
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presence of binucleated cells in SEC23B-silenced K562 cells (Fig. 2d,
indices 3, 6, 7); no binucleated cells were present in controls (Fig. 2d,
indices 1, 4 and 2, 5). Hematoxylin-eosin staining confirmed the
presence of binucleated cells (Fig. 2d, index 8). The major and minor
axes of SEC23B-silenced K562 nuclei were significantly increased in
size (Fig. 2d). These results support the hypothesis that the cell cycle
of erythroid cells and their cytokinesis depend on a sufficient level
of SEC23B.
To independently confirm the function of SEC23B in erythrocyte
development, we examined its role in zebrafish embryos using anti-
sense morpholino technology. The sec23b and the pu.1 translation-
blocking morpholinos18,19 were previously described. Efficacy of
the sec23b intron 4 splice donor–blocking morpholino (MO S) was
verified by RT-PCR (Fig. 3a). Injection of the sec23b translation-
blocking morpholino (MO A at 4 ng; data not shown) and the sec23b
MO S (1 ng, Fig. 3b) led to a pronounced reduction of the lower jaw
on day 3 post fertilization (d.p.f.) as observed previously in sec23b
and sec23a morphants18,20. Injection of a pu.1 translation-blocking
morpholino (4 ng) had no effect (data not shown). Given the
observation of the redundant function of SEC23A and SEC23B in
the maintenance of ERES and secretion of cargo, these findings must
be dissected in future experiments.
Erythrocytes from wild-type and pu.1 morphants were age-
appropriate on 3 d.p.f. and showed less than 0.2% (Table 1) well-
differentiated binucleated cells (Fig. 3c). However, erythrocytes in
sec23b morphants appeared larger, and we detected a significant
increase in immature, binucleated erythrocytes (Table 1 and
Fig. 3c) similar to that in human individuals with CDAII. We also
explored hypoglycosylation of band3, another hallmark of mature
erythrocytes of CDAII-affected individuals, in sec23b zebrafish mor-
phants. Although we observed underexpression of band3 in mor-
phants, we found no evidence of N-linked hypoglycosylation of band3
(Fig. 3d). Finally, duplication of rough ER, another CDAII character-
istic, was not seen in zebrafish erythrocytes with transmission electron
microscopy (data not shown). The sec23a mutant zebrafish line
crusher showed normal erythrocyte development (data not shown).
These observations are consistent with the idea that SEC23B has an
evolutionarily conserved function in erythrocyte development. The
failure to recapitulate the complete human phenotype in zebrafish
sec23b morphants may be due to lethality at 6 d.p.f.; morphant
erythropoiesis had to be scored at the larval stage with primitive
wave erythropoiesis while the erythroblasts from individuals with
CDAII are definitive wave hematopoiesis. We can speculate that the
two different programs have a differential requirement for sec23b such
as has been observed for many cytoskeletal membrane proteins
(band3, protein4.1 or b-spectrin).
Additional experiments (Supplementary Note) underscore the
erythrocyte specificity of SEC23B deficiency and the redundant func-
tion of human SEC23A and SEC23B in cells (fibroblasts, HeLa cells)
other than the erythroid lineage (Supplementary Figs. 1 and 2).
Alternatively, the cargo proteins carried by COPII vesicles may differ
between fibroblasts and HeLa cells versus erythroblasts, explaining the
lack of an obvious phenotype in these cells.
In conclusion, we have shown that mutations in SEC23B cause
CDAII. In some cases, a reduction in SEC23B expression occurs, which
in erythroblasts may not be sufficiently compensated for by SEC23A
a
b
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Figure 3 Analysis of sec23b zebrafish morphants. (a) Absence of wild-type
sec23b transcript in sec23b splice-blocking morphants. Embryos were either
left untreated (WT) or were injected at the 1- to 8-cell stage with sec23b
splice-blocking morpholino (MO S). (b) Brightfield images of wild-type (WT)
and sec23b MO S morphants obtained at 3 d.p.f. Red arrows indicate lower
jaw. Note the reduced jaw morphology in morphants compared to WT.
Magnification is 100. (c) Erythrocytes from pu.1 and sec23b MO A+S
morphants obtained at 3 d.p.f. Arrowheads point to binucleated erythrocytes.
Note immaturity, large size and perinuclear lucency (black arrow) of sec23b
morphant erythrocytes. Magnification is 100. A, translation blocking
MO; S, splice blocking MO; A+S, translation and splice blocking MO.
(d) Absence of structural differences of erythrocyte band3 (slc4a1) from
control and sec23b morphant embryos. Red blood cells were denatured for
either 65 1C or for 95 1C . Western blot was performed using anti-zebrafish
band3 antisera. Aggregates of band3 proteins were noted at higher
molecular weight irrespective of denaturation temperatures. As a loading
control, the same PVDF membrane was reprobed with anti-hsp60.
Table 1 Statistical analyses of jaw phenotype and erythroid
binuclearity in wild-type and morphant zebrafish
Evaluation of jaw morphology in morphants at 72 h.p.f.
Number of embryos
Type of embryo Normal Abnormal P valuea
Wild type 97 11
sec23b MOS 1 ng 0 175 o0.0001
Pu.1 MO A 4 ng 88 12 0.8254
Evaluation of erythrocyte binuclearity in morphants at 72 h.p.f.
Number of erythrocytes counted
Type of embryo Mononuclear Binuclear % P valuea
Wild type 3,286 6 0.18
sec23b MO S 1 ng 973 11 1.11 0.0004
sec23b MO A+Sb 1,870 38 2.03 o0.0001
pu.1 MO A 4 ng 1,442 2 0.14 0
h.p.f., hours post fertilization.
aComparing the number of embryos of the total with severe jaw phenotype or binuclearity
(Fisher exact test, two-tailed). bTo obtain maximal inhibition of Sec23 protein expression,
embryos were injected with a mixture of MO A (4 ng) and MO S (1 ng) (MO A+S).
NATURE GENETICS VOLUME 41 [ NUMBER 8 [ AUGUST 2009 93 9
LET TERS
 
 
©
20
09
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
and thus may result in erythrocyte-specific defects in COPII-mediated
ER export, ultimately leading to the clinical and cellular phenotype.
Incomplete cytokinesis is one of the key features of CDAII erythro-
cytes. The midbody is a transient ‘organelle-like’ structure remnant
of cell division just before abscission. SEC23B was identified in a screen
for midbody components21. Whether SEC23B plays an active role in
erythrocyte midbody assembly or deconstruction or whether glycosyla-
tion impairment indirectly affects cytokinesis remains to be established.
Mutations in genes encoding three COPII components have
been assigned to human genetic disorders. SAR1B defects cause the
chylomicron retention disease, Anderson disease and Marinesco-
Sjogren syndrome, resulting in lipid malabsorption22. SEC23A is
mutated in cranio-lenticulo-sutural dysplasia leading to skeletal
developmental defects17,20. SEC23B impairment is the basis of
CDAII. These studies are consistent with the hypothesis that COPII
components may act as membrane-coating modules with cargo
selectivity. Delineating additional genetic diseases caused by defects
in COPII components may help identify developmental and cell type–
specific tasks of each individual isoform of this secretory structure.
METHODS
Methods and any associated references are available in the online
version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. GenBank: RefSeq SEC23B DNA, NM_006363;
RefSeq SEC23B peptide, NP_006354.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Subjects. Subjects were collated in the German Registry on CDAs in Ulm,
Germany (F1 through F13) and the International Registry on CDAII in Naples,
Italy (F14 through F28). The diagnosis was based on history, clinical findings,
laboratory data, morphological analysis of aspirated bone marrow, evidence
of defective band3 glycosylation shown by SDS-PAGE and/or on increased
erythrocyte agglutination by antisera. In subjects F3P1 and F5P1, where SDS-
PAGE was not available, the diagnosis was confirmed by positive acidified
serum lysis test being specific for CDAII26.
The subjects gave informed consent for the studies. Collation of subject data
in the German Registry on CDAs and use of anonymized data and samples for
research were permitted by the ethical committee of the University of Ulm.
Cell lines and cell culture. Human primary dermal fibroblasts were grown in
Iscove’s Modified Dulbecco’s medium (IMDM, Gibco) supplemented with 10%
FCS (PAA) at 37 1C and 7.5% CO2. HEK-293T cells were cultivated in DMEM
(Gibco) plus 10% FCS at 37 1C and 7.5% CO2. K562 cells were grown in
IMDM (Sigma) supplemented with 10% FBS, 2 mM L-glutamine (Euro-clone)
and 1% (v/v) antibiotics (10,000 U/ml penicillin, and 10 mg/ml streptomycin
(Euro-clone)) at 37 1C and 5% CO2. For in vitro erythroid development,
CD34+ cells were isolated from the peripheral blood of nine healthy human
controls divided in three pools and plated on plastic culture dishes in
methylcellulose medium containing 3 U/ml erythropoietin (Janssen-Cilag) as
previously described27.
Genomic DNA preparation. Genomic DNA was prepared using the QIAamp
DNA Blood Kit (Qiagen).
SNP-analysis and homozygosity determination. Genotyping was conducted
on the Affymetrix GeneChip platform using the 50K Xba array of the
Affymetrix 100K system, which consists of about 50,000 SNPs (Affymetrix).
We subjected 250 ng of DNA to restriction endonuclease digestion by XbaI,
followed by processing according to the manufacturer’s instructions (see URLs
section for complete protocol). Arrays were hybridized, stained, washed and
scanned using a Hybridization Oven 640, Fluidics station FS450 and a
GeneChip Scanner 3000 7G according to the instructions of the manufacturer.
Genotying was conducted on the GTYPE Software 4.0 using the RLMM
genotype-calling algorithm. Homozygous regions were detected using CNAT4.0
(Affymetrix) and visualized with the IdeogramBrowser.
Genomic sequencing. For SEC23B exon sequencing, we amplified and
sequenced 100 ng genomic DNA (primers are available on request) with
a Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).
Sequence products were separated on an Applied Biosystems Prism 3100C
Genetic Analyzer.
RNA isolation and RT-PCR. RNA was isolated with the RNeasy Mini Kit
(Qiagen) followed by DNase digestion. We reverse transcribed 1 mg total
fibroblast RNA using the SuperScript II Reverse Transkriptase Kit (Invitrogen)
with random hexamer priming. Primers and conditions are available on request.
qRT-PCR. Total cellular RNA was extracted by a method described pre-
viously28. We carried out the RT reactions using the iScript cDNA Synthesis
Kit (BioRad), according to the manufacturer’s instructions. Quantitative real-
time qRT-PCR was performed using the SYBR Green PCR Master Mix
(Applied Biosystems) with the Applied Biosystem Model 7900HT Sequence
Detection System. Primers and conditions are available on request. Relative
gene expressions were calculated by using the 2DCt method, as previously
described29. The significance of the gene expression differences was deter-
mined using the Student’s t test. A two-sided P o 0.05 was considered
statistically significant.
Cloning of cDNA products into expression vectors. cDNA products were
purified with QIAquick PCR Purification Kit (Qiagen), cloned into pcDNA6/
myc-HIS- or pcDNA6/V5-HIS-vectors (Invitrogen) and transformed into the
XL-2blue bacterial Strain (Stratagene). Plasmids were purified with the QIA-
prep Miniprep Kit (Qiagen) and sequenced with the primers used for
generating the PCR products.
Transfection experiments. We nucleofected 2  106 HEK293T cells with a
total of 5 mg expression plamids (2.25 mg pcDNA6/myc-HIS vector, 2.25 mg
pcDNA6/V5-HIS-vector and 0.5 mg pEGFP-N1 vector) using Nucleofector Kit
V (Lonza). Following 48 h of cultivation, cell extracts were harvested in lysis
buffer (50 mM Tris pH 8.0, 62.5 mM EDTA, 1% Nonidet P-40 and 0.4%
deoxycholate). We transfected 0.8  106 K562 cells with 2.5 mg Expression
Arrest pSM2 retroviral shRNAmir plasmids (empty vector and nonsilencing
vector as controls, and shRNAmir plasmid against SEC23B) (Open Biosystems)
using TransIT-LT1 transfection reagent (Mirus). To select stable pools, 48 h
after transfection, the cells were cultured under 2 mg/ml puromycin (Invitrogen).
For sequence of shRNA, see Supplementary Table 5.
Coimmunoprecipitation experiments. After transfections, cell extracts were
prepared in immunoprecipitation buffer (25 mM Hepes pH 7.4, 150 mM KCl,
10 mM MgCl2, 10% glycerol, 0.1% Nonidet P-40, 2 mM DTT, and a protease
inhibitor cocktail). We incubated 400 mg extract with mouse antibody to V5
(R950-25, Invitrogen) (30 min, 4 1C) in a final volume of 500 ml immuno-
precipitation buffer followed by overnight incubation with Protein G Sepharose
(GE Healthcare). Precipitates were washed three times in immunoprecipitation
buffer before loading onto denaturing SDS gels.
Protein blotting. On an 8% SDS gel, 15 mg protein extract was loaded per lane.
After separation, the proteins were blotted semidry on an Immobilon-P
membrane (Millipore). First antibodies (mouse antibody to myc R950-25 or
mouse antibody to V5 R960-25) were used as 1:5000 solutions; secondary goat
anti-mouse antibodies coupled to horseradish peroxidase (HRP) were diluted
1:3000 (dilutions in: 10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20
and 5% milk powder). For SEC23B expression analysis of differentiated
CD34+ cells and K562 stable pools, a rabbit antibody to SEC23B (1:500;
Sigma) was used. HRP-conjugated anti-rabbit antibody (1:10,000) (Santa Cruz
Biotechnology) served as secondary antibody. A mouse antibody to b-actin
(1:5,000; Sigma-Aldrich) or a rabbit antibody to GAPDH (1:1,000; Cell
Signaling Technology) was used for control experiments. The blots were
developed with Super Script West Pico Chemoluminescent Substrate Kit
according to the manufacturer’s procedures (ThermoScientific).
Cell cycle analysis by flow cytometry. For cell cycle analysis, K562 stable pools
were collected by centrifugation, resuspended in PBS containing 3.75% Nonidet
P-40, 100 mg/ml RNase A and 40 mg/ml propidium iodide, and incubated at
room temperature for 3 h in the dark. Samples were analyzed on a FACScan
flow cytometer (Becton Dickinson Immunocytometry Systems, BDIS). The cell
cycle analysis was performed in triplicate with the program ModFit LT3.0.
Microscopic analysis of K562 stable pools. K562 cells and K562 stable pools
were fixed with 4% paraformaldehyde and centrifuged on cytospin slides.
Cytospin slides were stained by hematoxylin-eosin. Cells fixed were stained by
1 mg/ml DAPI and analyzed with a Zeiss axiovert 200M microscope equipped
with a plan-apochromat 63/1.4 oil immersion objective. The size of nuclei
major and minor axes were measured in pixels on DAPI images acquired by the
Zeiss axiovert 200M microscope. Numbers of nuclei analyzed were as follows:
18 nuclei for PSM2 stable pool, 19 for nonsilencing shRNAmir stable pool and
28 for SEC23B silencing stable pool.
Morpholino microinjection into zebrafish. We injected phosphorodiamidate
morpholino oligomers (morpholinos; Gene Tools) into wild-type Tu¨ strain
embryos at the 1- to 2-cell stage using a Harvard PLI-100 Pico-Injector
(Holliston). For morpholino sequences, see Supplementary Table 5.
RT-PCR of zebrafish RNA. Total RNA from 3 d.p.f. wild-type and morphant
larvae was prepared with TRIzol reagent (Invitrogen). Traces of genomic DNA
were removed by DNase-1 RNAse free digestion (Roche). Comparable amounts
of total RNA were subjected to reverse transcription with oligo-dT primers,
by using SuperScript III Reverse Transcriptase (Invitrogen) according to the
manufacturer’s instructions. PCR conditions wereas follows: 98 1C  3 min;
98 1C 15 s, 62 1C  30 s, 72 1C  90 s for 35 cycles; followed by 10 min
extension at 72 1C. For cDNA primer sequences, see Supplementary Table 5.
Analysis of zebrafish erythrocytes. For zebrafish blood collection, larvae at
3 d.p.f. were placed in lateral decubitus in a solution containing 0.9 PBS,
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1% BSA, 0.0002% heparin and 0.02% buffered solution of Tricaine methane-
sulfonate (MS222). We severed tails using a razor blade and collected blood
cells using a P20 pipettman. Blood cells were transferred into chilled Eppendorf
tubes containing 0.9 PBS and 1% BSA. Cells were pelleted in a micro-
centrifuge (100g, 10 min), resuspended in 300 ml 0.9 PBS and 1% BSA and
cytospun onto glass slides. Slides were Wright-Giemsa stained, and cells were
counted under light microscopy.
For protein blot of zebrafish erythrocytes, antisera directed against 14
C-terminal amino acid residues (C-LDADDANVKFDDED) of zebrafish band3
(also called anion exchanger 1, Slc4a1 and AE1) were generated in rabbits and
affinity-purified against the immunizing peptides (Genemed Synthesis)30.
Hsp60 antibody (sc-1722), goat anti-rabbit IgG-HRP (cat. no. sc-2054) and
donkey anti-goat IgG-HRP (sc-2020) are from Santa Cruz. We lysed and
denatured 1 PBS buffer-washed embryonic erythrocytes from control
and Sec23b morphant embryos of 3 d.p.f. with 1 volume of 2 Laemmli
SDS sample buffer (Biorad) under two conditions: 65 1C 10 min and 95 1C
5 min. Protein samples were separated on 10% acrylamide gels and transferred
on Immun-Blot PVDF membrane (Biorad). The membranes were probed
using antibody to band3 (1:5,000) with peroxidase-conjugated goat antibody to
rabbit IgG (Santa Cruz) as the secondary antibody (1:3,000). As a loading
control, membranes were re-probed using antibody to hsp60 (1:500) with
donkey antibody to goat IgG (Santa Cruz) as the secondary antibody (1:3,000).
The chemiluminescent method was used for detection (SuperSignal West Pico
Substrate, Pierce).
SEC23B structure. The model of human SEC23B was generated with MOD-
ELLER31 on the basis of the crystal structure of human SEC23A (protein data
bank code 2NUT).
FACS analysis of fibroblasts. We carried out multicolor flow cytometry
using a BD FacsAria with Diva 6.1 Software. For each antigen analyzed,
fluorochrome-coupled antibodies were used acording to the manufacturer’s
protocols (antibodies are available on request); as negative control, correspond-
ing fluorochrome-coupled isotypes were applied. GPI-anchored proteins were
detected with FLAER (Protox Biotech). PBS was used as a control for FLAER.
The fluorescence intensity of 100,000 cells was acquired.
Fibroblast differentiation assays. Adipogenic (Lonza), chondrogenic and
osteogenic (Miltenyi Biotech) differentiation of fibroblasts were performed
according to the manufacturers’ protocols.
Reagents for cell biology studies. Cycloheximide was from Calbiochem,
anti-SEC23 and anti-SEC23B sera were from Abcam, anti-Calnexin was from
Stressgene, anti-SEC31, anti-GM130 and anti-EEA1 were from BD Biosciences,
anti-Lamp1 (H4A3) was obtained from Developmental Studies Hybridoma
Bank, University of Iowa, anti-b-COP was described elsewhere32 and anti-
ts-O45-G monoclonal antibody ’VG’ recognizing an extra-cellular epitope of
the CFP-tagged vesicular stomatitis virus glycoprotein ts-O45-G was a gift from
K. Simons (Max Planck Institute of Molecular Cell Biology and Genetics).
Recombinant adenovirus encoding the cargo marker protein ts-O45-G tagged
with CFP was described33. Silencer siRNA duplexes against SEC23 were from
Ambion with the following siRNA identification numbers: 17796 (siSEC23A-1),
17702 (siSEC23A-2), 17795 (siSEC23B-1) and 17882 (siSEC23B-2). The sequence
of the control siScramble duplex is listed in Supplementary Table 5.
Cell culture and microinjection. HeLa-Kyoto cells (human cervix carcinoma
cells), a gift from S. Narumiya (Kyoto University) and T. Hirota (Institute of
Molecular Pathology, Vienna, Austria), and control as well as F4P1 fibroblasts
were maintained in DMEM (Life Technologies) supplemented with 10% FCS,
1% penicillin and streptomycin, and 1% glutamine in a 37 1C humidified
incubator with 5% CO2. For microinjection or immunostaining, cells were
grown on life cell dishes (MatTEk) or Lab-Tek II Chambered coverglass (Nunc)
or on 15-mm coverslips. Cells were microinjected using an Eppendorf micro-
injection system as previously described32. Injection markers were used at a
concentration of 0.4 mg/ml.
Transport assays. Cells were plated onto coverslips and siRNA transfections
were performed following the manufacturer’s recommendations using oligo-
fectamine. At 24 h after transfection, cells were infected with the CFP-ts-O45-
G-adenovirus and incubated at the nonpermissable temperature 39.5 1C and
5% CO2 for 16 h. To release the CFP-tagged ts-O45-G from the ER, we placed
the coverslips in a 32 1C water bath for 60 min followed by fixation.
Immunostaining. HeLa Kyoto cells, control and F4P1 fibroblasts were fixed
either with 100% methanol at 20 1C for 4 min or with 3% PFA for 20 min at
room temperature. PFA-treated cells were subsequently treated with 3% glycine
in PBS for 5 min and permeabilized with 0.1% Triton X-100 in PBS for an
additional 5 min. Fixed and permeabilized cells were incubated with primary
antibodies in PBS for 30 min. Samples were washed three times for 5 min in
PBS and then incubated for 30 min in Alexa-568 conjugated anti-rabbit or anti-
mouse secondary antibodies, and finally washed three times for 5 min in PBS.
Cells grown on coverslips were mounted on glass slides with Mowiol. Cells
grown on live cell dishes were left in PBS. All images were processed and
quantified using NIH ImageJ.
URLs. Assay manual, https://www.affymetrix.com/support/downloads/manuals/
100k_manual.pdf.
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